UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13D
Under the Securities Exchange Act of 1934
(Amendment No. 1)
Idera Pharmaceuticals, Inc
--------------------------------------------------------------------------------
(Name of Issuer)
Common Stock, par value $0.001 per share
--------------------------------------------------------------------------------
(Title of Class of Securities)
45168K108
----------------------------------------------------------------------
(CUSIP Number)
Leo Kirby
667 Madison Avenue, 17th Floor
New York, NY 10021
(212) 521-2418
--------------------------------------------------------------------------------
(Name, Address and Telephone Number of Person Authorized to Receive Notices and
Communications)
October 29, 2007
----------------------------------------------------------------------
(Date of Event which Requires Filing of this Statement)
If the filing person has previously filed a statement on Schedule 13G to report
the acquisition that is the subject of this Schedule 13D, and is filing this
schedule because of Rule 13d-1(e), 13d-1(f) or 13d-1(g), check the following
box. |X|
Note: Schedules filed in paper format shall include a signed original and five
copies of the schedule, including all exhibits. See Rule 13d-7 for other parties
to whom copies are to be sent.
*The remainder of this cover page shall be filled out for a reporting person's
initial filing on this form with respect to the subject class of securities, and
for any subsequent amendment containing information which would alter
disclosures provided in a prior cover page.
The information required on the remainder of this cover page shall not be deemed
to be "filed" for the purpose of Section 18 of the Securities Exchange Act of
1934 (the "Act") or otherwise subject to the liabilities of that section of the
Act but shall be subject to all other provisions of the Act (however, see the
Notes).
Page 1 of 6 Pages
SCHEDULE 13D
------------------- -----------------
CUSIP No. 45168K108 Page 2 of 6 Pages
------------------- -----------------
--------------------------------------------------------------------------------
1 NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS
Julian C. Baker
--------------------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)
(a) |_|
(b) |X|
--------------------------------------------------------------------------------
3 SEC USE ONLY
--------------------------------------------------------------------------------
4 SOURCE OF FUNDS (See Instructions)
WC
--------------------------------------------------------------------------------
5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS
2(d) OR 2(e) |_|
--------------------------------------------------------------------------------
6 CITIZENSHIP OR PLACE OF ORGANIZATION
United States
--------------------------------------------------------------------------------
NUMBER OF 7 SOLE VOTING POWER
SHARES
BENEFICIALLY 0
OWNED BY --------------------------------------------------------
EACH 8 SHARED VOTING POWER
REPORTING
PERSON 3,828,703
WITH --------------------------------------------------------
9 SOLE DISPOSITIVE POWER
0
--------------------------------------------------------
10 SHARED DISPOSITIVE POWER
3,828,703
--------------------------------------------------------------------------------
11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
3,828,703
--------------------------------------------------------------------------------
12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (See
Instructions) |_|
--------------------------------------------------------------------------------
13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
16.6%
--------------------------------------------------------------------------------
14 TYPE OF REPORTING PERSON (See Instructions)
IN
--------------------------------------------------------------------------------
Page 2 of 6 Pages
SCHEDULE 13D
------------------- -----------------
CUSIP No. 45168K108 Page 3 of 6 Pages
------------------- -----------------
--------------------------------------------------------------------------------
1 NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS
Felix J. Baker
--------------------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)
(a) |_|
(b) |X|
--------------------------------------------------------------------------------
3 SEC USE ONLY
--------------------------------------------------------------------------------
4 SOURCE OF FUNDS (See Instructions)
WC
--------------------------------------------------------------------------------
5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS
2(d) OR 2(e) |_|
--------------------------------------------------------------------------------
6 CITIZENSHIP OR PLACE OF ORGANIZATION
United States
--------------------------------------------------------------------------------
NUMBER OF 7 SOLE VOTING POWER
SHARES
BENEFICIALLY 0
OWNED BY --------------------------------------------------------
EACH 8 SHARED VOTING POWER
REPORTING
PERSON 3,828,703
WITH --------------------------------------------------------
9 SOLE DISPOSITIVE POWER
0
--------------------------------------------------------
10 SHARED DISPOSITIVE POWER
3,828,703
--------------------------------------------------------------------------------
11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
3,828,703
--------------------------------------------------------------------------------
12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (See
Instructions) |_|
--------------------------------------------------------------------------------
13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
16.6%
--------------------------------------------------------------------------------
14 TYPE OF REPORTING PERSON (See Instructions)
IN
--------------------------------------------------------------------------------
Page 3 of 6 Pages
This Amendment No. 1 to Schedule 13D is being filed by Julian C. Baker and
Felix J. Baker (the "Reporting Persons") to supplement the statements on
Schedule 13D previously filed by them, as heretofore amended. Except as
supplemented herein, such statements, as heretofore amended and supplemented,
remain in full force and effect.
Item 5. Interest in Securities of the Issuer.
Set forth below is the aggregate number of shares of Common Stock held,
including shares that maybe acquired upon the exercise of Warrants, as of the
date hereof by each of the following, together with the percentage of
outstanding shares of Common Stock that such number represents based upon
23,039,949 shares outstanding as reported in the Company's Form 10Q filed on
August 1, 2007. Such percentage figures are calculated on the basis that the
Warrants owned by the Reporting Persons are deemed exercised for shares of
Common Stock but other outstanding Warrants are not deemed converted or
exercised.
Percent of Class
Name Number of Shares Outstanding
---------------------------------- ----------- -------
Baker Bros. Investments, L.P. 118,514 0.5%
Baker Bros. Investments II, L.P. 107,105 0.5%
Baker Biotech Fund I, L.P 1,177,237 5.1%
Baker Brothers Life Sciences, L.P. 2,353,406 10.2%
14159, L.P. 72,441 0.3%
---------------------------------- ----------- -------
Total 3,828,703 16.6%
By virtue of their ownership of entities that have the power to control the
investment decisions of the limited partnerships listed in the table above,
Julian C. Baker and Felix J. Baker may each be deemed to be beneficial owners of
shares owned by such entities and may be deemed to have shared power to vote or
direct the vote of and shared power to dispose or direct the disposition of such
securities.
The following transactions in Common Stock were effected by the entities noted
below during the sixty days preceding the filing of this statement. None of the
reporting Persons has effected any other transactions in Common Stock during
this period.
-------------------------------------------------------------------------------------------
Number of Price/
Name Date Shares Transaction Share
-------------------------------------------------------------------------------------------
Baker Brothers Investments, L.P. 10/29/2007 1,743 Sale 12.4669
-------------------------------------------------------------------------------------------
Baker Brothers Investments II, 10/29/2007 1,574 Sale 12.4669
L.P.
-------------------------------------------------------------------------------------------
Baker Brothers Life Sciences,
L.P. 10/29/2007 34,606 Sale 12.4669
-------------------------------------------------------------------------------------------
Baker Biotech Fund I, L.P. 10/29/2007 17,311 Sale 12.4669
-------------------------------------------------------------------------------------------
14159, L.P. 10/29/2007 1,066 Sale 12.4669
-------------------------------------------------------------------------------------------
Page 4 of 6 Pages
-----------------------------------------------------------------------------------------------
Price/
Name Date Number of Shares Transaction Share
-----------------------------------------------------------------------------------------------
Baker Brothers Investments, L.P. 10/30/2007 1,628 Sale 12.0286
-----------------------------------------------------------------------------------------------
Baker Brothers Investments II, L.P. 10/30/2007 1,471 Sale 12.0286
-----------------------------------------------------------------------------------------------
Baker Brothers Life Sciences, L.P. 10/30/2007 32,332 Sale 12.0286
-----------------------------------------------------------------------------------------------
Baker Biotech Fund I, L.P. 10/30/2007 16,173 Sale 12.0286
-----------------------------------------------------------------------------------------------
14159, L.P. 10/30/2007 996 Sale 12.0286
-----------------------------------------------------------------------------------------------
Baker Brothers Investments, L.P. 10/31/2007 1,228 Sale 11.6995
-----------------------------------------------------------------------------------------------
Baker Brothers Investments II, L.P. 10/31/2007 1,109 Sale 11.6995
-----------------------------------------------------------------------------------------------
Baker Brothers Life Sciences, L.P. 10/31/2007 24,384 Sale 11.6995
-----------------------------------------------------------------------------------------------
Baker Biotech Fund I, L.P. 10/31/2007 12,198 Sale 11.6995
-----------------------------------------------------------------------------------------------
14159, L.P. 10/31/2007 751 Sale 11.6995
-----------------------------------------------------------------------------------------------
Item 7. Material to Be Filed as Exhibits.
Exhibit 1. Agreement regarding the joint filing of this statement.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify
that the information set forth in this statement is true, complete and correct.
October 31, 2007
By: /s/ Julian C. Baker
------------------------------
Julian C. Baker
By: /s/ Felix J. Baker
------------------------------
Felix J. Baker
Page 5 of 6 Pages
EXHIBIT 1
AGREEMENT
In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934,
as amended, the undersigned hereby agree that this Statement on Schedule 13D
relating to the Common Stock, $0.001 par value, of Idera Pharmaceuticals, Inc.
is being filed with the Securities and Exchange Commission on behalf of each of
them.
October 31, 2007
By: /s/ Julian C. Baker
------------------------------
Julian C. Baker
By: /s/ Felix J. Baker
------------------------------
Felix J. Baker
Page 6 of 6 Pages